Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Halozyme Therapeutics Inc’s stock clocked out at $48.06, down -1.13% from its previous closing price of $48.61. In other words, the price has decreased by -$1.13 from its previous closing price. On the day, 1.02 million shares were traded. HALO stock price reached its highest trading level at $48.64 during the session, while it also had its lowest trading level at $47.36.
Ratios:
To gain a deeper understanding of HALO’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.18 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.57. For the most recent quarter (mrq), Quick Ratio is recorded 9.15 and its Current Ratio is at 10.36. In the meantime, Its Debt-to-Equity ratio is 3.32 whereas as Long-Term Debt/Eq ratio is at 3.32.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on October 07, 2024, Downgraded its rating to Equal Weight and sets its target price to $62 from $58 previously.
On September 19, 2024, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also upped its target price recommendation from $52 to $57.
Piper Sandler Downgraded its Overweight to Neutral on June 07, 2024, whereas the target price for the stock was revised from $48 to $51.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 15 ’24 when LaBarre Michael J. sold 10,000 shares for $53.75 per share. The transaction valued at 537,469 led to the insider holds 173,756 shares of the business.
LaBarre Michael J. sold 10,000 shares of HALO for $532,590 on Oct 16 ’24. The SVP, CHIEF TECHNICAL OFFICER now owns 173,756 shares after completing the transaction at $53.26 per share. On Oct 16 ’24, another insider, MICHAEL LABARRE, who serves as the Officer of the company, bought 10,000 shares for $53.26 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HALO now has a Market Capitalization of 6184505344 and an Enterprise Value of 6983132672. As of this moment, Halozyme’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.90, and their Forward P/E ratio for the next fiscal year is 10.44. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.55. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.45 while its Price-to-Book (P/B) ratio in mrq is 13.50. Its current Enterprise Value per Revenue stands at 7.371 whereas that against EBITDA is 12.628.
Stock Price History:
Over the past 52 weeks, HALO has reached a high of $65.53, while it has fallen to a 52-week low of $33.15. The 50-Day Moving Average of the stock is -8.93%, while the 200-Day Moving Average is calculated to be -3.47%.
Shares Statistics:
It appears that HALO traded 1.65M shares on average per day over the past three months and 1730000 shares per day over the past ten days. A total of 127.18M shares are outstanding, with a floating share count of 125.86M. Insiders hold about 1.08% of the company’s shares, while institutions hold 99.34% stake in the company. Shares short for HALO as of 1731628800 were 10450111 with a Short Ratio of 6.35, compared to 1728950400 on 10416746. Therefore, it implies a Short% of Shares Outstanding of 10450111 and a Short% of Float of 11.1099996.
